增强益生菌的粘附/殖民效率通过聚糖表面装饰来缓解性结肠炎
Ting Liu1, Qiang Meng2, Yijun Zhang1
1College of Food Science and Technology, Northwest University, Xi'an, Shaanxi, 710069, China.
Probiotics and antimicrobial proteins
|July 11, 2025
概括
将益生菌包装在诸如奇托之类的材料中,可以增强它们在结肠中的附着性,从而改善性结肠炎 (UC) 的治疗. 这种方法克服了免费益生菌的问题,促进了肠道健康的治疗效果.
科学领域:
- 胃肠道学和微生物学
- 生物材料科学和药物交付 生物材料科学和药物交付
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性结肠疾病,其全球发病率正在增加.
- 口服益生菌对UC的疗效有限,原因是生存,殖民和治疗效果不佳.
研究的目的:
- 为了研究UC改变的胃肠道环境和益生菌-粘膜相互作用.
- 探索用于增强益生菌结肠粘附和UC治疗的封装材料.
主要方法:
- 分析UC胃肠道中的生理化学变化.
- 评估封装材料 (酸盐,酸盐,酸酸) 用于结肠向.
- 评估粘附机制 (静电吸附,键,二硫化键) 和材料降解.
主要成果:
- 封装材料可以准结肠壁,延长益生菌的肠粘附时间.
- 特定的材料通过静电吸附,键或二硫化物键形成来促进粘附.
- 总结了封装材料的降解模式和潜在影响.
结论:
- 具有结肠粘附性质的益生菌微囊可以使用特定的封装策略来制备.
- 这项研究为治疗性结肠炎的多糖基益生菌的临床应用提供了建议.
相关概念视频
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
680
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
680
Drugs for Treatment of Ulcerative Colitis in IBD
236
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
236
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
316
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
316
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
595
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
595
Drugs for Treatment of Constipation-Predominant IBS
322
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
322
Inflammatory Bowel Disease IV: Pharmacological Management
177
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
177


